Holen Sie sich die Stockscreener-App
4.38
3.79%
0.16
Handel nachbörslich:
4.38
Schlusskurs vom Vortag:
$4.22
Offen:
$4.25
24-Stunden-Volumen:
264.31K
Relative Volume:
0.27
Marktkapitalisierung:
$153.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.60M
KGV:
-1.5464
EPS:
-2.8324
Netto-Cashflow:
$-67.37M
1W Leistung:
+4.53%
1M Leistung:
+61.03%
6M Leistung:
-34.33%
1J Leistung:
-68.76%
1-Tages-Spanne:
$4.16
$4.49
1-Wochen-Bereich:
$3.91
$4.49
52-Wochen-Spanne:
$1.45
$19.50
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Vergleichen Sie LXEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
4.38 | 153.01M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
Bank of America Corp DE Trims Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics files to sell 41.63M shares of common stock for holders - MSN
Lexeo Therapeutics (LXEO) Proposes Sale of 41.63 Million Shares - GuruFocus
Lexeo Therapeutics Registers Share Offering on Behalf of Selling Stockholders - MarketScreener
Lexeo Therapeutics (LXEO) Proposes Sale of 41.63 Million Shares | LXEO Stock News - GuruFocus
Jane Street Group LLC Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stake Lifted by Wellington Management Group LLP - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Acquired by Millennium Management LLC - Defense World
Deutsche Bank AG Buys 8,378 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Wilson Sonsini Advises Lexeo Therapeutics on $80 Million Private Placement Equity Financing - Wilson Sonsini
Lexeo Therapeutics (NASDAQ:LXEO) Given New $10.00 Price Target at JPMorgan Chase & Co. - Defense World
Leerink Partnrs Issues Optimistic Outlook for LXEO Earnings - Defense World
Lexeo Therapeutics (LXEO) Price Target Lowered by JP Morgan | LX - GuruFocus
Lexeo Therapeutics (LXEO) Price Target Lowered by JP Morgan | LXEO Stock News - GuruFocus
BNP Paribas Financial Markets Buys 28,986 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Northern Trust Corp Acquires 14,185 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo raises $80 million to shore up gene therapy work after layoffs - The Pharma Letter
Leerink cuts Lexeo Therapeutics price target to $10, maintains outlook - Investing.com Australia
Leerink cuts Lexeo Therapeutics price target to $10, maintains outlook By Investing.com - Investing.com India
Lexeo Therapeutics raises $80M in private placement (LXEO) - Seeking Alpha
Lexeo Therapeutics secures $80 million in private placement By Investing.com - Investing.com South Africa
Lexeo Therapeutics (LXEO) Secures $80M from Private Placement | - GuruFocus
Lexeo Therapeutics Announces $80 Mln Private Placement Of Shares - Nasdaq
Lexeo Therapeutics Announces $80 Million Equity Financing - marketscreener.com
Lexeo prices 20.8M shares at $2.8825 in private placement - TipRanks
Lexeo Therapeutics Announces $80M Private Placement Agreement - TipRanks
Lexeo Therapeutics (LXEO) Secures $80M from Private Placement | LXEO Stock News - GuruFocus
Lexeo Therapeutics secures $80 million in private placement - Investing.com
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases - The Manila Times
Lexeo Therapeutics Secures $80 Million Financing to Extend Cash Runway into 2028 for Clinical Programs - Nasdaq
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of ... - Bluefield Daily Telegraph
Major Investors Back Lexeo Therapeutics with $80M for Breakthrough Genetic Heart Disease Programs - Stock Titan
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of “Buy” by Brokerages - Defense World
Price T Rowe Associates Inc. MD Acquires New Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Q1 Earnings Forecast for LXEO Issued By HC Wainwright - Defense World
FY2025 Earnings Forecast for LXEO Issued By Chardan Capital - Defense World
HC Wainwright Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $15.00 - Defense World
Lexeo stock price target cut to $15 by H.C. Wainwright - Investing.com South Africa
Lexeo Therapeutics price target lowered to $15 from $23 at H.C. Wainwright - TipRanks
Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Superior Safety Profile Drive Buy Rating - TipRanks
#ASGCT25: In three patients, Rocket’s second heart gene therapy shows promise - Endpoints News
Lexeo Therapeutics (LXEO) Analyst Rating Update and Price Target Adjustment | LXEO Stock News - GuruFocus
Lexeo Therapeutics (LXEO) Price Target Cut to $15 by H.C. Wainwr - GuruFocus
Leerink Partnrs Has Bearish Forecast for LXEO Q2 Earnings - Defense World
Chardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price - Defense World
Lexeo Therapeutics: Strategic Focus and Promising Pipeline Drive Buy Rating - TipRanks
Lexeo Therapeutics (LXEO) Sees Price Target Adjustment by Charda - GuruFocus
Chardan Adjusts Price Target on Lexeo Therapeutics to $20 From $22, Maintains Buy Rating - marketscreener.com
Lexeo Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
Lexeo Therapeutics price target lowered to $20 from $22 at Chardan - TipRanks
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexeo Therapeutics Inc-Aktie (LXEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Adler Eric | Chief Medical Officer |
May 16 '25 |
Sale |
2.77 |
585 |
1,623 |
67,681 |
| Robertson Jenny | Chief Legal Officer |
May 16 '25 |
Sale |
2.77 |
521 |
1,445 |
63,098 |
| See Tai Sandi | Chief Development Officer |
May 16 '25 |
Sale |
2.77 |
367 |
1,018 |
59,242 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):